<!doctype html>
<html>
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport" content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="AstraZeneca | LYNPARZA">
<title>AstraZeneca | LYNPARZA</title>
<link rel="stylesheet" type="text/css" href="css/animate.min.css" />
<link rel="stylesheet" type="text/css" href="css/style.css" />
<script src="http://ajax.googleapis.com/ajax/libs/jquery/1.9.1/jquery.min.js"></script>
<style type="text/css">

.feature {width:735px; height:435px;  background-image: url('./img/significantreduction_graph.png'); background-repeat: no-repeat;
background-size: 100%;
}
.footText {margin-top: 10px; font-family: "HelveticaNeueLTStd"; line-height: 16px; font-size: 12px; color: #506061;}

ul { list-style: none; }
.footnote {word-spacing: -0.166em; }


.bodyContentLeft {margin-top: 236px; margin-left: 68px; width:440px; height:305px;}
.bodyContentRight {width:458px; height:231px; margin-top: -263px; margin-left: 540px;}
.bodyContentRight > li, .bodyContentLeft > li { margin-bottom: 15px;  line-height: 23px;}
h4 {font-size:24px; font-family: "lexiRegular"; margin-bottom: 24px;}

ul { list-style: none; font-family: "HelveticaNeueLTStd"; font-size:18px; color: white; }
.bodyContentRight > li:first-child {margin-left:-15px;}
.bodyContentRight > li:nth-child(2), .bodyContentRight > li:nth-child(3) {list-style: disc;}
.bodyContentRight > li:last-child {font-size:14px; font-family: "HelveticaNeueLTStd";}


/*.graphLines{width:770px; height:315px;  position: relative; margin-left:60px;}
.graphLines > li:first-child {transform: rotate(270deg); font-size: 14px; color:#3f4444; 
    font-family: "HelveticaNeueLTStd"; position: absolute; margin-left:-250px; margin-top:170px;}
ul{list-style: none;}
.graphLines > ul {position:absolute; }
.graphLines > ul:nth-child(2){border-left: 1px solid black;}
.graphLines > ul:nth-child(2) > li:first-child {margin-top: -5px;}
.graphLines > ul:nth-child(2) > li{ position: relative; margin-bottom: 70px; margin-left: -35px; font-size:14px; color:#3f4444;}
.graphLines > ul > li:last-child {margin-bottom: 5px;}
.graphLines > ul:nth-child(2) > li:nth-child(5) {margin-bottom: 5px;}
.graphLines > ul:nth-child(3) { margin-left:-10px; border-top:1px solid black; margin-top: 368px;}
.graphLines > ul:nth-child(3) > li { display: inline-block;  margin-left:100px; margin-top:20px;  font-size:14px; color:#3f4444;}
.graphLines > ul:nth-child(3) > li:first-child{margin-left: 6px;}*/


.close > p { font-family:"proximaBold"; font-size:30px; color: white; margin-left: 4px; margin-top: 4px;}
.logo, .popup, .controls, .popup .ref, .close, .inner-close, .bull li:before, .note, .info { position:absolute; }
.close, .inner-close { right: 15px; top: 15px; width:30px; height:30px; /*background: url('../img/close.png') 0 0 no-repeat;*/ border:1px solid #fff; -webkit-border-radius:100px; z-index:10;  }

    .contents > .close, .inner-close { border-color:#787878; background-position-y:-23px; display:none; }
    .video .close { background:#1b3e58; }
    
.nav .close { background:none; top:-50px; right:8px; }
    .nav .close:before { color:#004d74; }
.close, .inner-close, .logo, .info, .bull li:before { background-size:100% auto; }


</style> 

</head>
<body>
  <div class="popup">
            <span class="close"><p>X</p></span>
                    <ul class="bodyContentLeft">
                        <h4>Welte <em>et al.</em> study design:</h4>
                        <li>A 12-week, randomised, double-blind, parallel-group<br />
                            study in 660 patients (≥40 yrs) with moderate-severe<br />COPD (FEV<sub>1</sub> ≤50% predicted normal and a history<br />
                            of exacerbations requiring systemic steroids<br /> and/or antibiotics).
                        </li>
                        <li>Patients received tiotrpium (18Ug) once-daily plus either<br />Symbicort<sup>&reg;</sup> 400/12ug or placebo twice daily. Terbutaline
                        <br />0.5mg was used as reliever medication as-needed<br />throughout the run in and treatment period. The primary<br />
                        outcome was clinic pre-dose FEV<sub>1</sub> evaluated as <br /> change from randomisation to 12 weeks.
                        </li>

                    </ul>
                    <ul class="bodyContentRight">
                        <li>Over 12 weeks of treatment:<sup>1</sup></li>
                        <li>Symbicort 400/12 bd + tiotropium significantly<br /> prolonged time to first exacerbation vs. tiotropium<br />+ placebo; 
                            <em>p< 0.001</em></li>
                        <li>Symbicort 400/12 bd + tiotropium significantly<br />improved post-dose FEV<sub>1</sub> by 11% (at both 5 and<br />
                            60 minutes post-dose) vs. tiotropium + placebo;<br /><em>p< 0.001</em>
                        </li>
                        <li>Reference: 1. Welte T <em>et al. Am J Respir Crit Care Med.</em> 2009; 180:741-50.
                    </ul>
        </div>
	<section id="container">
	<header>
		<p>Significant reduction in exacerbations*<br />and hospitalisations when Symbicort is added to Spiriva<sup>&reg1</sup></p>
         <p>*Exacerbations defined as worsening of COPD requiring use of systemic corticosteroids (oral or parenteral) and/or
         hospitalisation.<br />Secondary endpoint, primary endpoint was met. 12 week study.</p>
	</header>
        <ul class="controls">
            <li class="r">R</li>
            <li class="s disb">S</li>
        </ul>
    	<article class="content">

        <div class="feature"></div>

            <!--<ul class="graphLines">
                <li>Exacerbations/patient</li>
                    <ul>
                        <li>0.4</li>
                        <li>0.3</li>
                        <li>0.2</li>
                        <li>0.1</li>
                        <li>0.0</li>
                    </ul>
                    <ul>
                        <li>0</li>
                        <li>15</li>
                        <li>30</li>
                        <li>45</li>
                        <li>60</li>
                        <li>75</li>
                        <li>90</li>
                    </ul>
            </ul>-->

    		<p class="footnote">Adapted from Welte et al. 2009.1 A 12-week, randomised, double-blind, parallel-group study in 660 patients (≥40 yrs) with moderate-severe COPD (FEV1 ≤50% predicted normal and a history of exacerbations requiring systemic steroids and/or antibiotics).<br />
            Reduction in rate of exacerbations and hospitalisations at 12 weeks; Symbicort 400/12 bd + tiotropium 18µg od vs. tiotropium 18µg od + placebo.<br />
            Reference: 1. Welte T <em>et al. Am J Respir Crit Care Med</em> 2009; 180:741–750.</p>

        </article>

    </section>

<script type="text/javascript" src="js/jquery-1.11.0.min.js"></script>
<script type="text/javascript" src="js/touchy.js"></script>
<script type="text/javascript" src="js/script.js"></script>
<script type="text/javascript">
	$( function(){
        $(".popup").css("display","none");
        $(".s").click(function(){
            $("#container").css("display","none");
            $("body").css("background-color","rgba(101,105,105,0.80)");

            $(".popup").css("display","block");
        });
        $(".r").click(function(){
            //If reference Button Clicked
        });
	});



</script>
</body>
</html>
